Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

NCT02045446 ↗

Phase 2 Completed 29 enrolled University of Texas Southwestern Medical Center

RandomizedParallel-groupOpen-labelTreatment

Summary

The core hypothesis to be tested is that the use of consolidative SBRT followed by maintenance chemotherapy in patients with less than or equal to 6 metastatic sites (primary + 5) will improve progression free survival (PFS) compared to maintenance chemotherapy alone.

Timeline

Start: 2014-02
Primary completion: 2022-02-17
Completion: 2022-05-02

Publications

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501. Epub 2018 Jan 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Bevacizumab	Monoclonal antibody	—	—
Background	Docetaxel	Small molecule	—	—
Background	Erlotinib	Small molecule	—	—
Background	Gemcitabine	Small molecule	—	—
Background	Pemetrexed	Small molecule	—	—

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

Summary

Timeline

Publications

Drugs

Indications